From checkpoint inhibitors like PD1 to innate immunity molecules like STING, therapeutics utilizing the innate immune system to jumpstart the effects of the adaptive system are currently in development. Join this webinar and take part of a discussion with experts (Andrea van Elsas, Jeremy R Graff, and Timo K. van den Berg) about current research about immune checkpoint and last trends for the future.
Main topics :
Andrea van Elsas, PhD
Chief Scientific Officer Aduro Biotech, Inc.
Jeremy R Graff, PhD
President and Chief Scientific Officer Biothera Pharmaceuticals, Inc.
Timo K. van den Berg, PhD
Professor (Immunotherapy), Dept. Molecular Cell Biology and Immunology VU Medical Center Head, Dept. Blood Cell Research, Sanquin Research Academic Medical Center Amsterdam
Immune responses are controlled by an exquisite system of either stimulatory or inhibitory checkpoints. Cancer cells often find a way to utilize these checkpoints to avoid being attacked by the immune system. Drugs that block checkpoints, checkpoint inhibitors, mainly targeting the adaptive immune system, are now clinically available for use against certain types of cancer. Now, new therapeutics utilizing the innate immune system to jumpstart the effects of the adaptive system are currently in development. The innate immune system itself also expresses checkpoint molecules that have been shown to either enhance or dampen anti-tumor immunity. There is growing interest in blocking inhibitory innate immune checkpoints such as the “don’t eat me” signal CD47, which is commonly overexpressed on cancer cells, and the TAM receptor family of tyrosine kinases. Moreover, small molecule agonists against STING – a protein that ramps up production of interferons and cytokines – are major targets on the radar for therapeutic development, as well as molecules that target Toll-like Receptors (TLRs) and RIG-I-like Receptors (RLRs).
Join us for a discussion about first-in-class STING agonists and innate immune checkpoints in cancer, and bring your questions and comments.